Siramesine alone had no effect on tumor size, but did reduce the percentage of CD133+ and CD133+/CXCR4+ in PDAC3 tumors; however, this effect was not sufficient to reduce tumor growth at the dosage used (30 mg/kg). Here, CXCR4 is linked to neoplasm.